NINE MONTH FINANCIAL RESULTS

Diagnostics group DiaSorin's nine-month adjusted core profit up 6%

The group's nine-month overall revenue grew to 583 million euros compared to last year's results of 846 million euros, driven by the excellent performance of CLIA speciality tests in the immunodiagnostics segment, which rose 10% yearly, the company said in a statement.